We unleash your business potential by maximize the business innovation.
Send EmailTranexamic Acid, Cyclo Capron, Transamin, Trans AMCHA, AMCA, 1197-18-8
TRANEXAMIC ACID
SECTION 1: PRODUCT IDENTITY AND CHEMICAL IDENTIFICATION
| Parameter | Information |
|---|---|
| Product Name | Tranexamic Acid |
| Chemical Name (IUPAC) | trans-4-(Aminomethyl)cyclohexanecarboxylic acid |
| Synonyms (Turkish) | Traneksamik Asit, AMCA, trans-AMCHA |
| Synonyms (English) | Tranexamic Acid, AMCA, trans-AMCHA, Cyclocapron, Transamin |
| CAS Number | 1197-18-8 |
| EC Number (EINECS) | 214-818-2 |
| Molecular Formula | C₈H₁₅NO₂ |
| Molecular Weight | 157.21 g/mol |
| Chemical Class | Amino acid derivative; Antifibrinolytic agent |
| Pharmacological Class | Antifibrinolytic; Plasminogen inhibitor |
| Physical State (20°C) | Solid (crystalline powder) |
| Color | White to off-white |
| Odor | Odorless |
| Taste | Slightly bitter |
SECTION 2: CHEMICAL STRUCTURE
COOH
|
C
/ \
/ \
/ \
/ \
/ \
/ \
C C
| |
C——CH₂——NH₂ C
| |
C C
\ /
\ /
\ /
\ /
\ /
\ /
C
Tranexamic Acid
trans-4-(Aminomethyl)cyclohexanecarboxylic acid
C₈H₁₅NO₂
Simplified Structure:
HOOC — (C₆H₁₀) — CH₂NH₂
Tranexamic Acid
(trans-isomer)
| Parameter | Description |
|---|---|
| Molecular Formula | C₈H₁₅NO₂ |
| Molecular Weight | 157.21 g/mol |
| Chemical Class | Amino acid derivative (cyclohexane carboxylic acid) |
| Functional Groups | Carboxylic acid (-COOH), primary amine (-CH₂NH₂) |
| Isomerism | trans-isomer (active form); cis-isomer (inactive) |
| SMILES | C1CC(CCC1CN)C(=O)O |
| InChI | InChI=1S/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)/t6-,7- |
| InChI Key | GYDJEQRTZSCIOI-LJGSYFOKSA-N |
| Hydrogen Bond Donors | 2 |
| Hydrogen Bond Acceptors | 3 |
| Rotatable Bond Count | 2 |
| Polar Surface Area (PSA) | 63.3 Ų |
| Optical Activity | Optically active (trans-isomer) |
| Chirality | 2 stereocenters |
SECTION 3: PHYSICAL AND CHEMICAL PROPERTIES
| Property | Value | Test Method / Note |
|---|---|---|
| Appearance | White to off-white crystalline powder | Visual |
| Odor | Odorless | Olfactometric |
| Molecular Weight | 157.21 g/mol | Calculated |
| Melting Point | ~300°C (decomposes) | DSC / Capillary |
| Density (20°C) | ~1.2 g/cm³ (estimated) | - |
| Water Solubility (20°C) | High (>100 g/L) | General Method |
| Hot Water Solubility | Very high | General Method |
| Ethanol Solubility | Slightly soluble (~5-10 g/L) | General Method |
| Methanol Solubility | Soluble | General Method |
| Acetone Solubility | Practically insoluble | General Method |
| Chloroform Solubility | Insoluble | General Method |
| Ether Solubility | Insoluble | General Method |
| Log P (Octanol/Water) | < -1.0 (very hydrophilic) | Calculated / Experimental |
| pKa | ~4.3 (carboxylic acid); ~10.6 (amine) | Potentiometric |
| pH (1% Solution) | ~5.0 – 7.0 | pH Meter |
| Vapor Pressure (25°C) | Very low | - |
| Flash Point | >150°C | - |
| Thermal Stability | Stable up to 200°C; decomposes at higher temperatures | - |
| Hygroscopicity | Low (not hygroscopic) | - |
| Optical Rotation [α]D²⁰ | +14° to +16° (c=1, H₂O) | Polarimetry |
| UV Maximum (λmax) | None (no UV absorption) | UV-VIS Spectrophotometer |
| Heat of Solution | Exothermic (when dissolved in water) | - |
| Surface Activity | Low | - |
SECTION 4: PHARMACOLOGICAL PROPERTIES AND MECHANISM OF ACTION
| Property | Description |
|---|---|
| Pharmacological Class | Antifibrinolytic agent |
| Mechanism of Action | Competitively inhibits plasminogen activators (tissue plasminogen activator - tPA, urokinase) that convert plasminogen to plasmin; Reduces plasmin formation; Inhibits fibrin breakdown (fibrinolysis); Maintains blood clot stability. |
| Lysine Binding Site | Binds to lysine binding sites (kringle domains) on plasminogen; Blocks interaction of plasminogen with activators. |
| Antifibrinolytic Potency | Approximately 6-10 times more potent than aminocaproic acid (EACA) |
| Oral Bioavailability | ~30-50% (with first-pass metabolism) |
| Peak Plasma Concentration (Cmax) | 10-20 µg/mL (after 25 mg/kg oral dose) |
| Peak Time (Tmax) | ~2-3 hours (oral) |
| Plasma Half-Life (t½) | ~2-3 hours |
| Protein Binding | Low (~3-5%) |
| Volume of Distribution (Vd) | ~0.3 L/kg |
| Metabolism | Minimal (<5%); Mainly excreted unchanged |
| Elimination | • Urine: ~90-95% (unchanged) • Feces: ~5-10% |
| Renal Clearance | Equivalent to plasma clearance (~90-110 mL/minute) |
| Elimination Half-Life | Prolonged in renal failure |
| Pregnancy Category | FDA Category B |
| Maximum Daily Dose | 3-4 g/day (IV); 2-6 g/day (oral) |
SECTION 5: CLINICAL USE AND INDICATIONS
| Indication | Formulation | Dose | Route | Duration |
|---|---|---|---|---|
| Surgical Bleeding Control | IV Injection | 10-15 mg/kg (bolus); 1-2 mg/kg/hour (infusion) | Intravenous | Throughout surgery |
| Cardiopulmonary Bypass (CABG) | IV | 10-30 mg/kg bolus; 1-10 mg/kg/hour infusion | Intravenous | During bypass |
| Heavy Menstrual Bleeding | Tablet | 500-1000 mg, 3 times daily (days 1-5) | Oral | 3-5 days |
| Postpartum Hemorrhage | IV / Oral | 1 g (IV); 500 mg (oral), 2-3 times daily | IV / Oral | 3-5 days |
| Dental Surgery (Hemophilia) | Tablet / IV | 10-25 mg/kg, 2-3 times daily | Oral / IV | 2-7 days |
| Trauma (Injury) | IV | 1-2 g bolus; 1-2 mg/kg/hour infusion | Intravenous | 8-24 hours |
| Melasma (Hyperpigmentation) | Topical | 2-3% cream / lotion | Topical | 8-12 weeks |
| Systemic Allergic Reactions | Topical / Oral | Variable | Topical / Oral | Symptomatic |
| Menorrhagia | Tablet | 500-1000 mg, 3 times daily | Oral | 3-5 days/cycle |
| Subarachnoid Hemorrhage | IV | 1-2 g/day | Intravenous | Variable |
SECTION 6: COMMERCIAL GRADES AND VARIANTS
| Grade / Type | Purity | Particle Size | Primary Application |
|---|---|---|---|
| Pharmaceutical Grade (USP/EP) | ≥99.0% | Standard | Tablet, injectable solution production |
| Research Grade (R&D) | ≥99.5% | Standard | Analytical standards, formulation development |
| GMP Grade | ≥99.0% | Standard / Micronized | Pharmaceutical manufacturing |
| Analytical Standard | ≥99.8% | Standard | HPLC reference standards |
| Topical Grade | ≥99.0% | Micronized (optional) | Cream, lotion formulations |
| Veterinary Grade | ≥98.0% | Standard | Animal bleeding control |
SECTION 7: FORMULATION GUIDELINES
| Parameter | Recommendation |
|---|---|
| Oral Tablet Formulation | • Lactose, MCC, sodium starch glycolate, povidone, magnesium stearate • Strength: 500 mg, 750 mg, 1000 mg |
| Injectable Solution | • 100 mg/mL (10 mL ampoule) • pH: 6.5-7.5 • Isotonic adjustment (NaCl) • Light-protected ampoule |
| Topical Cream (2-3%) | • O/W emulsion • Transdermal penetration enhancers • pH: 5.0-6.0 |
| Solubility Enhancement | High water solubility; additional solvents not required |
| pH Range | Optimum pH 5.0-7.0; Stable in acidic or basic conditions |
| Compatibility | Compatible with most excipients; Avoid strong oxidizing agents |
| Temperature Processing | Dissolve at 60-70°C; avoid high temperatures (>100°C) causing degradation |
| Sterilization | Autoclaving possible (121°C, 15 minutes); Aseptic filtration (0.2 µm) |
| Color | Colorless solution (injection); White tablet |
| Preservatives | Injectable formulations do not require preservatives; Can be added for multi-dose formulations |
SECTION 8: QUALITY SPECIFICATIONS (USP/EP)
| Parameter | USP / EP Specification | Test Method |
|---|---|---|
| Appearance | White to off-white crystalline powder | Visual |
| Assay (on dried basis) | ≥99.0% - ≤101.0% | HPLC / Titrimetric |
| Melting Point | ~300°C (decomposes) | Capillary |
| pH (1:100 Solution) | 5.0 – 7.0 | pH Meter |
| Water Content | ≤0.5% | Karl Fischer |
| Residue on Ignition | ≤0.1% | Gravimetric |
| Heavy Metals (Pb) | ≤10 ppm | ICP-MS / USP <231> |
| Arsenic (As) | ≤2 ppm | ICP-MS |
| Lead (Pb) | ≤3 ppm | ICP-MS |
| Cadmium (Cd) | ≤1 ppm | ICP-MS |
| Mercury (Hg) | ≤1 ppm | ICP-MS |
| Related Substances (Single) | ≤0.2% | HPLC |
| Related Substances (Total) | ≤0.5% | HPLC |
| Chloride (Cl) | ≤0.02% | Titrimetric |
| Sulfate (SO₄) | ≤0.05% | Turbidimetric |
| Particle Size | As per customer specification | Laser Diffraction |
| Microbiological Purity | TAMC ≤10² CFU/g; TYMC ≤10¹ CFU/g | USP <61> |
| E. coli | Negative in 1g | USP <62> |
| Salmonella spp. | Negative in 25g | USP <62> |
| S. aureus | Negative in 1g | USP <62> |
| P. aeruginosa | Negative in 1g | USP <62> |
| Optical Rotation | +14° to +16° (c=1, H₂O) | Polarimetry |
SECTION 9: TOXICOLOGICAL PROFILE
| Parameter | Value |
|---|---|
| Acute Oral Toxicity (LD50, Rat) | >5000 mg/kg (very low toxicity) |
| Acute Dermal Toxicity (LD50, Rabbit) | >2000 mg/kg (low toxicity) |
| Skin Irritation | May cause mild irritation |
| Eye Irritation | May cause mild irritation |
| Skin Sensitization | Does not cause sensitization |
| Carcinogenicity | Not classified as carcinogenic |
| Mutagenicity | Not mutagenic (AMES test negative) |
| Reproductive Toxicity | Fetotoxic potential at high doses; Pregnancy Category B |
| Target Organs | Kidneys, liver, gastrointestinal system |
| Common Side Effects | • Nausea (5-10%) • Vomiting (2-5%) • Diarrhea (2-5%) • Headache (2-5%) |
| Serious Side Effects | • Thromboembolic complications (rare) • Anaphylactic reactions (very rare) • Color vision disturbances (long-term high dose) |
| Thromboembolic Risk | Use with caution in patients with history of active thromboembolic disease |
| NOAEL (Rat, 90 days) | ~500 mg/kg/day |
| Therapeutic Window | Wide; low toxicity |
SECTION 10: GHS CLASSIFICATION AND LABELING
GHS Classification (in accordance with 1272/2008/EC):
| Hazard Class | Category | H-Statement |
|---|---|---|
| Generally not classified as hazardous substance | – | – |
| Skin Irritation | Category 2 (optional) | H315 |
| Eye Irritation | Category 2 (optional) | H319 |
Signal Word: None (Not classified as hazardous) or Warning (optional)
Hazard Pictograms: None (generally) or GHS07 (Exclamation mark)
NFPA 704 Hazard Classification:
| Health | Flammability | Reactivity | Special |
|---|---|---|---|
| 1 | 0 | 0 | - |
| (Minimal health hazard) | (Non-combustible) | (Stable) | (None) |
SECTION 11: PRECAUTIONARY STATEMENTS (P-CODES)
| Code | Statement |
|---|---|
| P261 | Avoid breathing dust/fume/gas |
| P264 | Wash hands thoroughly after handling |
| P270 | Do not eat, drink or smoke when using this product |
| P271 | Use only outdoors or in a well-ventilated area |
| P280 | Wear protective gloves/protective clothing/eye protection/face protection |
| P301+P312 | IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell |
| P302+P352 | IF ON SKIN: Wash with plenty of soap and water |
| P304+P340 | IF INHALED: Remove person to fresh air and keep comfortable for breathing |
| P305+P351+P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and continue rinsing |
| P332+P313 | If skin irritation occurs: Get medical advice/attention |
| P337+P313 | If eye irritation persists: Get medical advice/attention |
| P362+P364 | Take off contaminated clothing and wash it before reuse |
| P403+P233 | Store in a well-ventilated place. Keep container tightly closed |
| P405 | Store locked up |
| P501 | Dispose of contents/container in accordance with local/regional/national/international regulations |
SECTION 12: FIRST AID MEASURES
| Route of Exposure | Action |
|---|---|
| Inhalation | If inhaled as powder, move to fresh air. Seek medical attention if respiratory symptoms persist. |
| Skin Contact | Remove contaminated clothing. Wash with plenty of soap and water. Seek medical attention if irritation develops. |
| Eye Contact | Rinse thoroughly with plenty of water for at least 15 minutes. Keep eyelids open. Remove contact lenses if present. Seek medical attention if irritation persists. |
| Ingestion | Rinse mouth with water. Do NOT induce vomiting. Drink 1-2 glasses of water. Seek medical attention. |
| Note | Symptomatic treatment is administered. No specific antidote available. |
SECTION 13: ADVERSE EFFECTS AND MANAGEMENT
| Adverse Effect | Frequency | Severity | Management |
|---|---|---|---|
| Nausea | Common (5-10%) | Mild | Take with meals; dose reduction |
| Vomiting | Common (2-5%) | Mild | Take with meals; antiemetics |
| Diarrhea | Common (2-5%) | Mild | Increase fluid intake; probiotics |
| Headache | Common (2-5%) | Mild | Analgesics; rest |
| Dizziness | Less common (1-2%) | Mild | Rest; move slowly |
| Thromboembolic Events | Rare (<0.5%) | Serious | Discontinue treatment; emergency medical attention |
| Anaphylactic Reaction | Very rare (<0.1%) | Serious | Discontinue treatment; emergency medical attention |
| Color Vision Disturbance | Rare (long-term high dose) | Moderate | Dose reduction; ophthalmologic examination |
SECTION 14: CONTRAINDICATIONS AND WARNINGS
| Condition | Description |
|---|---|
| Active Thromboembolic Disease | Use with caution; History of deep vein thrombosis, pulmonary embolism, cerebrovascular event |
| Color Vision Disturbance | Risk of retinal damage with long-term high-dose therapy; Regular eye examinations |
| Renal Failure | Dose adjustment required (GFR <30 mL/minute) |
| Hematuria (Upper Urinary) | Risk of urinary tract obstruction; Evaluation of urinary system |
| Pregnancy | FDA Category B; No teratogenic effects in animal studies; Use only if clearly necessary |
| Lactation | Excreted in breast milk (low concentration); Use with caution |
| Drug Interactions | • Concomitant use with anticoagulants (warfarin, heparin) • Interaction with thrombolytic agents (streptokinase, tPA) |
| Pediatric Use | Safety data limited; Dose adjustment required |
| Elderly Patients | Dose adjustment based on renal function |
SECTION 15: DRUG INTERACTIONS
| Drug / Substance | Interaction Type | Severity | Management |
|---|---|---|---|
| Anticoagulants (Warfarin, Heparin) | Anticoagulant effect potentially increased | Moderate | INR monitoring; dose adjustment |
| Thrombolytic Agents (Streptokinase, tPA, Urokinase) | Antifibrinolytic effect; Thrombolytic effect reduced | Moderate-Serious | Concomitant use not recommended |
| Factor IX Complex Concentrates | Thrombotic risk increased | Moderate | Use with caution |
| Oral Contraceptives | Thromboembolic risk increased (theoretical) | Low | Monitoring |
| Desmopressin | Hemostatic effect increased (synergy) | Positive | Combination may be beneficial |
| Estrogens | Thromboembolic risk increased (theoretical) | Low | Monitoring |
SECTION 16: STORAGE AND SHELF LIFE
| Parameter | Information |
|---|---|
| Storage Conditions | Store in a cool (<25°C), dry, well-ventilated area; protect from direct sunlight and moisture. |
| Temperature Limits | 15-25°C (ideal); do not exceed 30°C |
| Humidity | Low humidity environment (not hygroscopic) |
| Light | Protect from UV light and direct sunlight |
| Oxygen | Protect against oxidation; keep containers tightly closed |
| Incompatible Materials | Strong oxidizing agents, strong acids, strong bases |
| Container Requirements | Light-proof, moisture-proof containers: Amber glass, aluminum foil, HDPE |
| Shelf Life | 36-60 months (unopened original packaging, under proper storage conditions) |
| Shelf Life (After Opening) | 12-24 months (under proper storage conditions) |
| Signs of Degradation | Color change (yellowing), caking, decreased solubility, HPLC impurity increase |
| Stability Warning | Stable under normal conditions; May degrade under high temperature and humidity |
SECTION 17: PACKAGING OPTIONS
| Packaging Type | Quantity / Capacity | Material | Application Area |
|---|---|---|---|
| Fiber Drum (PE Lined) | 25 kg | Fiber / PE liner | Pharmaceutical manufacturing, industrial supply |
| HDPE Drum | 25 kg, 50 kg | HDPE (opaque, moisture barrier) | Pharmaceutical, industrial supply |
| Aluminum Foil Bag | 1 kg, 5 kg, 10 kg | Aluminum / PE (light and moisture proof) | High purity, pharmaceutical |
| Amber Glass Bottle | 100 g, 500 g, 1 kg | Amber glass (UV protected) | Laboratory, analytical standards |
| Kraft Bag (PE Lined) | 10 kg, 25 kg | Kraft paper / PE liner | Economical packaging |
| IBC Container | 500 kg, 1000 kg | UV-protected HDPE | Large-scale industrial supply |
SECTION 18: TRANSPORTATION INFORMATION
| Parameter | Information |
|---|---|
| UN Number | Not applicable (not classified as dangerous substance) |
| Hazard Class | Not applicable |
| Packing Group | Not applicable |
| ADR/RID | Not classified as dangerous goods |
| IMDG Code | Not marine pollutant; not classified as dangerous goods |
| IATA (Air) | Not classified as dangerous goods; can be transported by air |
| Transport Temperature | Ambient temperature; protect from heat, moisture, and light |
| Transport Precautions | Light-proof packaging; keep away from strong oxidizing agents |
| Spill Cleanup | Collect mechanically; clean with absorbent material; avoid dust generation |
| Marine Pollutant | No |
SECTION 19: REGULATORY STATUS
| Region / Authority | Status |
|---|---|
| USA (USP/NF) | Official monograph (Tranexamic Acid) |
| European Pharmacopoeia | Official monograph (Tranexamic Acid) |
| USA (FDA) | Prescription drug; Approved (IV, oral, topical forms) |
| WHO Essential Medicines List | Essential medicine (antifibrinolytic) |
| Turkey | Licensed pharmaceutical active ingredient; Prescription drug; KKDIK registered |
| ECHA (REACH) | Registered substance |
| TSCA (USA) | Listed |
| DEA / Controlled Substance | Not a controlled substance |
| IARC | Not classified (not carcinogenic) |
| NTP | Not listed |
| California (Prop 65) | Not listed |
SECTION 20: OTHER NAMES AND SYNONYMS
| Type | Name |
|---|---|
| Chemical Name (IUPAC) | trans-4-(Aminomethyl)cyclohexanecarboxylic acid |
| Common Names (Turkish) | Traneksamik Asit, AMCA |
| Common Names (English) | Tranexamic Acid, AMCA, trans-AMCHA, Cyclocapron, Transamin |
| Trade Marks | Cyklokapron®, Transamin®, Tranex®, Exacyl®, Lysteda® |
| CAS Number | 1197-18-8 |
| EC Number | 214-818-2 |
| PubChem CID | 5526 |
| DrugBank ID | DB00302 |
| FDA UNII | 6T84R30KC1 |
| ATC Code | B02AA02 |
SECTION 21: SUMMARY TABLE
| Parameter | Value |
|---|---|
| CAS Number | 1197-18-8 |
| Molecular Formula | C₈H₁₅NO₂ |
| Molecular Weight | 157.21 g/mol |
| Appearance | White to off-white crystalline powder |
| Melting Point | ~300°C (decomposes) |
| Water Solubility | High (>100 g/L) |
| pKa | ~4.3 (carboxylic); ~10.6 (amine) |
| Primary Function | Antifibrinolytic agent |
| Main Indications | Surgical bleeding, menorrhagia, trauma, dental surgery, melasma |
| Maximum Daily Dose | 3-4 g/day (IV); 2-6 g/day (oral) |
| Plasma Half-Life | ~2-3 hours |
| Bioavailability | ~30-50% (oral) |
| Shelf Life | 36-60 months |
| Storage | Cool (<25°C), dry, light-protected |
| GHS Classification | Generally not hazardous |
| FDA Pregnancy Category | B |
| UN Number | Not applicable |
SECTION 22: CRITICAL WARNINGS AND BEST PRACTICES
CRITICAL WARNINGS:
Thromboembolic Risk: Use with caution in patients with history of active thromboembolic disease. Risk of deep vein thrombosis, pulmonary embolism, or cerebrovascular events.
Renal Failure: Dose adjustment required (GFR <30 mL/minute). Risk of accumulation at high doses.
Color Vision Disturbance: Risk of retinal damage with long-term high-dose therapy; Regular eye examinations.
Hematuria (Upper Urinary): Risk of urinary tract obstruction; Urinary system should be evaluated.
Pregnancy: FDA Category B; Use only if clearly necessary.
Lactation: Excreted in breast milk (low concentration); Use with caution.
Drug Interactions: Avoid concomitant use with anticoagulants and thrombolytic agents.
Pediatric Use: Safety data limited; Dose adjustment required.
Elderly Patients: Dose adjustment based on renal function.
BEST PRACTICE RECOMMENDATIONS:
Dosage: For surgical bleeding control: 10-15 mg/kg IV bolus, followed by 1-2 mg/kg/hour infusion. For menorrhagia: 500-1000 mg oral, 3 times daily.
Dose in Renal Failure: GFR 30-60 mL/minute: 50% dose; GFR <30 mL/minute: 25% dose.
Administration: Oral forms should be taken with meals (GI tolerance). IV form should be administered as slow injection (>1 minute).
Monitoring: Periodic eye examinations (color vision, visual acuity) should be performed during long-term therapy.
Stability: Stable under normal conditions; 60 months shelf life. Protect from high temperature and humidity.
Quality Control: Assay (HPLC), melting point, pH, water content, heavy metals, microbiological purity tests should be performed regularly.
Formulation: Injectable solutions: pH 6.5-7.5; Isotonic adjustment; Light-protected ampoules.
Patient Education: Inform patients about side effects (nausea, vomiting, headache) and thromboembolic symptoms (leg pain, swelling, shortness of breath).
Microbiological Control: Powder form should be tested for microbiological contamination (TAMC, TYMC, pathogens).
Spill Cleanup: Avoid dust generation; use HEPA-filtered vacuum or wet cleaning. Prevent entry into water and sewers.
LEGAL DISCLAIMER:
The information provided in this document is based on our current knowledge and experience and is presented in good faith. However, as all conditions of use are beyond our control, it does not constitute a binding specification or guarantee. This Technical Data Sheet is for informational purposes only and does not constitute medical advice. Users are responsible for testing suitability for their own applications and for complying with all local, regional, and national regulations. For complete safety, storage, use, handling, waste, and regulatory compliance information, please refer to the official Safety Data Sheet (SDS/MSDS) provided by the manufacturer/supplier. Tranexamic Acid is a prescription medication; its use must be under the supervision of a healthcare professional.